News | November 03, 2021
Lancet endorses Sputnik Light for safety and immune response
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
Subscribe To Our Newsletter & Stay Updated
